Factor Therapeutics logo

FTT - Factor Therapeutics Share Price

A$0.004 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £2.22m
Enterprise Value £430k
Revenue £1.28m
Position in Universe 1621st / 1836
Bullish
Bearish
Unlock FTT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FTT Revenue Unlock FTT Revenue

Net Income

FTT Net Income Unlock FTT Revenue

Normalised EPS

FTT Normalised EPS Unlock FTT Revenue

PE Ratio Range

FTT PE Ratio Range Unlock FTT Revenue

Dividend Yield Range

FTT Dividend Yield Range Unlock FTT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FTT EPS Forecasts Unlock FTT Revenue
Profile Summary

Factor Therapeutics Limited, formerly Tissue Therapies Limited, is a biotechnology company. The Company's principal activities include the development and commercialization of its intellectual property in wound care. The Company's lead program, VF-001, is a biologic product for wound care. VF-001 can be used in conjunction with standard care compression bandaging in the community setting. VF-001 is a fusion protein between a truncated vitronectin peptide and Insulin-like growth factor 1(IGF-1). The initial indication for VF-001 is for Venous Leg Ulcers (VLUs). The Company also has other programs in early development to address other wound applications, as well as new products in the ocular wound care space. Its pipeline includes VF-002, a viscous product to assess burn potential, particularly mucosal burns from radiation therapy, and VF-003 and VF-004, for growth in eye procedures/use of glaucoma stents, reduction of fibrosis and minimization of negative effects of ocular surgery.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 6, 2002
Public Since March 19, 2004
No. of Shareholders: 2,392
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,042,835,633
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FTT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FTT
Upcoming Events for FTT
Wednesday 25th March, 2020 Estimate
Factor Therapeutics Ltd Annual Shareholders Meeting
Similar to FTT
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.